TBD | 1.50 credits (1.50 pharmacology) | $40.00

TBD | 1.50 credits (1.50 pharmacology) | $40.00

The 2018 Agricultural Improvement Act (Farm Bill 2018) authorized by Congress made hemp products containing less than 0.3% tetrahydrocannabinol (THC) legal. However, contrary to popular belief, this bill did not authorize the legal sale of cannabidiol (CBD) products for promotion of any traditional health benefits, yet the sale of CBD products across the United States has significantly increased following its passage. There is currently no formal regulation on CBD products being sold in the United States beyond Epidiolex® which is specifically regulated as a drug via the FDA. Pharmacists need to understand the basics of how CBD acts on the human body, which health claims have been proven via robust clinical trials, and the potential adverse effects and drug interactions that may occur in a patient who uses these unregulated products in conjunction with their prescribed or over-the-counter medication regimen. Pharmacists also need to be able to provide information regarding the sale and regulation of CBD products and the potential issues that may arise given the current legal status of CBD products. | 1.50 credits (1.50 pharmacology) | $40.00

Over the past 20+ years, new therapies for IBD and IBS continue to be approved and strategies for the management of these (very different) disease states continue to evolve. This presentation will help practitioners understand the differences between IBD and IBS, as well as the differences in treatment options for ulcerative colitis (UC) and Crohn’s disease (CD). The emergence of numerous monoclonal antibodies have changed the landscape of how we manage patients with IBD, eliminating long-standing challenges like steroid-dependence, but have created new challenges in how we monitor these potentially toxic medications. New drugs for IBS are continually being developed and this presentation will explore how these medications work as well as their current role in the management of IBS. | 1.50 credits (1.50 pharmacology) | $40.00

Most patients with asthma are managed by primary care providers and not by specialists. This session will summarize the advances in the evaluation and management of asthma from basics to biologics using updated 2021 GINA guidelines. Treatment of difficult asthma, especially severe asthma and asthma/COPD overlap will be discussed. Management of asthma during the covid19 pandemic will be reviewed. Use of personalized medicine with biologics and new drugs in development for asthma will be reviewed. The challenges of delivering healthcare in rural and other environments with lower access to resources will be incorporated in all treatment approaches. | 1.50 credits (1.50 pharmacology) | $40.00

This presentation reviews the physiology of the CYP450 metabolic cascade and its function in preparing drugs for excretion. Based upon a foundation of physiology, the day-to-day implications of safe prescribing are presented with case study illustrations and analysis. | 1.50 credits (1.50 pharmacology) | $45